Search

everythinglearnresearchcommunity

for

Search:↓

Early diagnosis and treatment are crucial for skin emergencies and drug reactions.

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

DHT may reduce inflammation caused by certain bacteria in skin cells.

Researchers developed a 3D skin model with its own immune and blood vessel cells to better understand skin health and disease.

Atopic dermatitis in kids with alopecia areata can predict poor response to topical immunotherapy.

Injury boosts normal skin cell growth, reducing cancer cell advantage.

Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.

CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.

BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.

A patient with granuloma annulare experienced both isotopic and isomorphic responses, with skin lesions responding to steroids but relapsing after stopping treatment.

Recognizing RSCC is crucial due to its aggressive nature and high risk of poor outcomes.

Targeted immunotherapies may offer better treatment for alopecia areata by controlling inflammation and immune responses.

An 8-year-old boy developed a rare condition after a liver transplant, which improved after changing his medication.

A woman on immunosuppressants developed two rare scalp conditions, which improved with specific treatments.

Mice genetically modified to produce more CD109 in their skin had less inflammation and better healing with less scarring.

Hair follicles in nonsegmental vitiligo are better protected from immune attacks than in alopecia areata.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

The dog had a good prognosis with proper treatment and cleaning.

Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.

Targeting specific biomarkers and immune signals is more effective and safer for treating inflammatory skin diseases.

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Consider infectious diseases like visceral leishmaniasis before diagnosing autoimmune hepatitis.

Thymus transplantation successfully restored immune function in infants with FOXN1 deficiency.

A 70-year-old woman with bronchiectasis developed a rare immune disease due to a bacterial infection, requiring a difficult balance of treatments.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

Non-immune dermal cells dominate, epidermal cells increase after day 9, and certain immune cells persist beyond inflammation in wound-induced hair follicle regeneration.